Opsumit® (macitentan) is an orally available endothelin receptor antagonist (ERA) that resulted from a tailored drug discovery process with the target of developing an ERA to address efficacy and safety.
Actelion’s lead product, Tracleer® (bosentan) – an endothelin receptor antagonist – was the first oral treatment approved for PAH.
Uptravi® (selexipag), originally discovered and synthesized by Nippon Shinyaku, is the only approved oral selective IP receptor agonist targeting the prostacyclin pathway in pulmonary arterial hypertension.
Veletri® (Epoprostenol for Injection) is intravenous prostacyclin. Unlike other epoprostenol formulations approved for PAH, Veletri is stable at room temperature (77 F, 25 C) for up to 48 hours when administered immediately upon reconstitution and dilution, making the use of frozen gel packs unnecessary.
Valchlor® (mechlorethamine) gel 0.016% is applied topically once-a-day and dries on the skin. Valchlor is the only US Food and Drug Administration (FDA) approved topical formulation of mechlorethamine, a chemotherapeutic agent for the treatment of early stage mycosis fungoides, a type of Cutaneous T-Cell Lymphoma.